Ralph A. DeFronzo, MD discusses the Noxious Nine and the impact of hypercortisolism on difficult-to-control type 2 diabetes.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

Matthew Weir, MD discusses how a multidisciplinary approach is reshaping CKD management, with a focus on mitigating cardiovascular events.

Lower CD4+ cell counts, HCV genotype 4, and recent injection drug use were linked to unsuccessful DAA treatment in people with HCV and HIV.

These data provide insight into characteristics of those who choose to discontinue systemic therapies for eczema.

Panelists discuss how bempedoic acid offers a promising alternative for patients who are statin-intolerant, demonstrating efficacy in reducing major cardiovascular events and low-density lipoprotein cholesterol, while addressing its role in managing residual cardiovascular risk, particularly in high-risk populations.

Matsushita discussed findings from the OLE FRONTIER4 study of Mim8.

Panelists discuss their advice for dermatologists managing chronic spontaneous urticaria (CSU), emphasizing the importance of individualized treatment plans, and staying updated on emerging therapies and clinical guidelines.

Panelists discuss the unmet needs in chronic spontaneous urticaria (CSU) management, highlighting the evolution of the field toward more personalized and effective treatment strategies to address refractory symptoms.

The AASM has updated its RLS guidelines, now recommending against the standard use of dopamine agonists due to evidence of augmentation.

Despite having a lower risk of hospitalization, cardiovascular events, and mortality, patients with IgAN and FSGS had a higher risk of CKD progression.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

Erin Michos, MD examines unique HFpEF mechanisms for women and implications for sex-specific treatment.

Matino discussed data from the phase 3 BASIS study evaluating the recently approved Hympavzi.

Patients with hypercortisolism and difficult-to-control type 2 diabetes who received mifepristone exhibited a significant HbA1c improvement in the Phase 4 trial.

The FDA awarded Breakthrough Therapy Designation to Vir Biotechnology’s tobevibart and elebsiran for the treatment of chronic hepatitis delta.

This assessment of dupilumab for pediatric and adult patients with moderate-to severe eczema treated for up to 5 years confirms the drug efficacy and safety across age groups.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

The BCG-unresponsive non-muscle invasive bladder cancer space has gone from a dearth of options to a wave of new treatments.

An FDA review of postmarket clinical trial data revealed an increased risk of liver injury with obeticholic acid in patients with PBC without cirrhosis.

To celebrate surpassing 100 episodes, Diabetes Dialogue sits down with Irl Hirsch, MD, to discuss the 25-year anniversary of continuous glucose monitoring in 2024.

These long-term results from the ADjoin trial show that long-term lebrikizumab therapy may improve sleep disturbances, pruritus, and skin symptoms, using POEM as an assessment tool.

Patients with schizophrenia and COVID-19 both present dysregulated energy metabolism, explaining the high COVID-19 rates among those with schizophrenia.

Patients with IBS had different dietary patterns than matched general population controls, with poor diet diversity and quality linked to symptom severity.